"Lymphoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A general term for various neoplastic diseases of the lymphoid tissue.
| Descriptor ID |
D008223
|
| MeSH Number(s) |
C04.557.386 C15.604.515.569 C20.683.515.761
|
| Concept/Terms |
Lymphoma- Lymphoma
- Lymphomas
- Sarcoma, Germinoblastic
- Germinoblastic Sarcoma
- Germinoblastic Sarcomas
- Sarcomas, Germinoblastic
- Reticulolymphosarcoma
- Reticulolymphosarcomas
- Germinoblastoma
- Germinoblastomas
- Lymphoma, Malignant
- Lymphomas, Malignant
- Malignant Lymphoma
- Malignant Lymphomas
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma".
Below are MeSH descriptors whose meaning is more specific than "Lymphoma".
This graph shows the total number of publications written about "Lymphoma" by people in this website by year, and whether "Lymphoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 2 | 3 |
| 1998 | 0 | 2 | 2 |
| 1999 | 2 | 0 | 2 |
| 2000 | 4 | 2 | 6 |
| 2001 | 2 | 0 | 2 |
| 2002 | 1 | 3 | 4 |
| 2003 | 3 | 0 | 3 |
| 2004 | 1 | 1 | 2 |
| 2005 | 4 | 3 | 7 |
| 2006 | 2 | 4 | 6 |
| 2007 | 2 | 1 | 3 |
| 2008 | 2 | 2 | 4 |
| 2009 | 4 | 2 | 6 |
| 2010 | 3 | 0 | 3 |
| 2011 | 6 | 3 | 9 |
| 2012 | 2 | 3 | 5 |
| 2013 | 5 | 1 | 6 |
| 2014 | 9 | 4 | 13 |
| 2015 | 5 | 0 | 5 |
| 2016 | 5 | 2 | 7 |
| 2017 | 7 | 0 | 7 |
| 2018 | 7 | 0 | 7 |
| 2019 | 7 | 0 | 7 |
| 2020 | 6 | 0 | 6 |
| 2021 | 16 | 1 | 17 |
| 2022 | 10 | 0 | 10 |
| 2023 | 11 | 0 | 11 |
| 2024 | 6 | 1 | 7 |
| 2025 | 7 | 0 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphoma" by people in Profiles.
-
Impact of sociodemographic determinants on enrollment into contemporary lymphoma clinical trials: a systematic review. Oncologist. 2025 Jun 04; 30(6).
-
Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Relapsed or Refractory Lymphoma. Clin Lymphoma Myeloma Leuk. 2025 Sep; 25(9):e649-e655.
-
Exercise-induced ?2-adrenergic receptor activation enhances effector lymphocyte mobilization in humans and suppresses lymphoma growth in mice through NK-cells. Brain Behav Immun. 2025 Aug; 128:751-765.
-
Innovative Algorithm for Incidence of Leukemia and Lymphoma in the U.S. Military Health Care System. Mil Med. 2025 Apr 23; 190(5-6):e1184-e1189.
-
Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas. Blood Adv. 2025 Apr 08; 9(7):1658-1669.
-
Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure. Leuk Lymphoma. 2025 Aug; 66(8):1437-1446.
-
Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma. Clin Cancer Res. 2025 Mar 17; 31(6):975-982.
-
Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation. Blood. 2025 Mar 06; 145(10):1047-1060.
-
Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium. J Natl Cancer Inst. 2024 Nov 01; 116(11):1721-1729.
-
Radiation target nomenclature for lymphoma trials: consensus recommendations from the National Clinical Trials Network groups. Lancet Haematol. 2024 Dec; 11(12):e951-e958.